References
- Algaier I, Jakubowski JA, Asai F, von Kügelgen I. (2008). Interaction of the active metabolite of prasugrel, R-138727, with cysteine 97 and cysteine 175 of the human P2Y12 receptor. J Thromb Haemost 6:1908–14.
- Baillie TA. (2016). Targeted covalent inhibitors for drug design. Angew Chem Int Ed Engl 55:13408–21.
- Bentley D, Young AM, Rowell L, et al. (2012). Evidence of a drug-drug interaction linked to inhibition of ester hydrolysis by orlistat. J Cardiovasc Pharmacol 60:390–6.
- Campbell CL, Berger PB, Nuttall GA, et al. (2005). Can N-acetylcysteine reverse the antiplatelet effects of clopidogrel? An in vivo and vitro study. Am Heart J 150:796–9.
- Charman WNA, Stella VJ. (1986). Estimating the maximal potential for intestinal lymphatic transport of lipophilic drug molecules. Int J Pharma 34:175–8.
- Chiba T, Kitoo H, Toshioka N. (1973). [Studies on thiol and disulfide compounds. I. Absorption distribution metabolism and excretion of 35 S-2-mercaptopropionylglycine]. Yakugaku Zasshi 93:112–8.
- Derks M, Fowler S, Kuhlmann O. (2009). A single-center, open-label, one-sequence study of dalcetrapib coadministered with ketoconazole, and an in vitro study of the S-methyl metabolite of dalcetrapib. Clin Therap 31:586–99.
- Derks M, Busse-Reid R, Kuhlmann O, Paehleret A. (2010). [14C]-dalcetrapib ADME following a single oral dose in healthy male subjects. Clin Pharmacol Therap 87:S9–S37.
- Derks M, Anzures-Cabrera J, Turnbull L, Phelan M. (2011). Safety, tolerability and pharmacokinetics of dalcetrapib following single and multiple ascending doses in healthy subjects: A randomized, double-blind, placebo-controlled, Phase I study. Clin Drug Investigation 31:325–35.
- Gross G, Tardio J, Kuhlmann O. (2012). Solubility and stability of dalcetrapib in vehicles and biological media. Int J Pharma 437:103–9.
- Harada D, Naito S, Otagiri M. (2002). Kinetic analysis of covalent binding between N-acetyl-L-cysteine and albumin through the formation of mixed disulfides in human and rat serum in vitro. Pharma Res 19:1648–54.
- Hartmann G, Kumar S, Johns D, et al. (2016). Disposition into adipose tissue determines accumulation and elimination kinetics of the cholesteryl ester transfer protein inhibitor anacetrapib in mice. Drug Metab Disposit 44:428–34.
- Heald AF, Ita CE, Singhvi SM, Migdalof BH. (1985). Tissue distribution of 14C- and 35S-captopril in rats after intravenous and oral administration. Xenobiotica 15:51–6.
- Ichihashi T, Kinoshita H, Takagishi Y, Yamada H. (1992). Effect of oily vehicles on absorption of mepitiostane by the lymphatic system in rats. J Pharma Pharmacol 44:560–4.
- Khoo SM, Edwards GA, Porter CJH, Charman WN. (2001). A conscious dog model for assessing the absorption, enterocyte-based metabolism, and intestinal lymphatic transport of halofantrine. J Pharma Sci 90:1599–607.
- Lonsdale R, Ward RA. (2018). Structure-based design of targeted covalent inhibitors. Chem Soc Rev 47:3816–30.
- Okamoto H, Yonemori F, Wakitani K, et al. (2000). A cholesteryl ester transfer protein inhibitor attenuate atherosclerosis in rabbits. Nature 406:203–7.
- Park BK, Grabowski PS, Yeung JHK, Breckenridge AM. (1982). Drug protein conjugates–I. A study of the covalent binding of [14C]captopril to plasma proteins in the rat. Biochem Pharmacol 31:1755–60.
- Ray S, Murkin AS. (2019). New electrophiles and strategies for mechanism-based and targeted covalent inhibitor design. Biochemistry 58:5234–44.
- Takubo H, Ishikawa T, Kuhlmann O, et al. (2014). Pharmacokinetics and disposition of dalcetrapib in rats and monkeys. Xenobiotica 44:1117–26.
- Wetterau JR, Zilversmit DB. (1986). Localization of intracellular triacylglycerol and cholesteryl ester transfer activity in rat tissues. Biochim Biophys Acta 875:610–7.